Effectiveness of BA.1-and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

被引：11

作者：

Arashiro, Takeshi ^{[1
,2
,3
,4
]}

Arima, Yuzo ^{[1
]}

Kuramochi, Jin ^{[5
,6
]}

Muraoka, Hirokazu ^{[7
]}

Sato, Akihiro ^{[8
]}

Chubachi, Kumi ^{[9
]}

Yanai, Atsushi ^{[10
]}

Arioka, Hiroko ^{[10
]}

Uehara, Yuki ^{[11
,12
]}

Ihara, Genei ^{[13
]}

Kato, Yasuyuki ^{[14
]}

Yanagisawa, Naoki ^{[15
]}

Ueda, Akihiro ^{[16
]}

Kato, Hideaki ^{[17
]}

Oka, Hideaki ^{[18
]}

Nishida, Yusuke ^{[18
]}

Nidaira, Yuki ^{[5
]}

Asami, Takahiro ^{[19
]}

Jinta, Torahiko ^{[20
]}

Nakamura, Akira ^{[21
]}

Oba, Kunihiro ^{[22
]}

Taniyama, Daisuke ^{[23
]}

Yamamoto, Kei ^{[18
]}

Tanaka, Katsushi ^{[17
]}

Ueshima, Kankuro ^{[24
]}

Fuwa, Tetsuji ^{[24
]}

Stucky, Ashley ^{[1
]}

Suzuki, Tadaki ^{[2
]}

Smith, Chris ^{[3
]}

Hibberd, Martin ^{[3
]}

Ariyoshi, Koya ^{[4
]}

Suzuki, Motoi ^{[1
]}

机构：

[1] Natl Inst Infect Dis, Ctr Surveillance Immunizat & Epidemiol Res, Tokyo, Japan

[2] Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan

[3] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England

[4] Nagasaki Univ, Sch Trop Med & Global Hlth, Nagasaki, Japan

[5] Kuramochi Clin Interpk, Tochigi, Japan

[6] Tokyo Med & Dent Univ, Dept Global Hlth Promot, Tokyo, Japan

[7] Clin TAMACHI, Tokyo, Japan

[8] KARADA Internal Med Clin, Tokyo, Japan

[9] Chubachi Internal Resp Med Clin, Tokyo, Japan

[10] St Lukes Int Hosp, Dept Gen Internal Med, Tokyo, Japan

[11] St Lukes Int Hosp, Dept Clin Lab, Tokyo, Japan

[12] Fujita Hlth Univ, Sch Med, Dept Infect Dis, Aichi, Japan

[13] Machida Ekimae Naika Clin, Tokyo, Japan

[14] Int Univ Hlth, Welf Narita Hosp, Dept Infect Dis, Chiba, Japan

[15] Yanagisawa Clin, Tokyo, Japan

[16] Japanese Red Cross Med Ctr, Dept Infect Dis, Tokyo, Japan

[17] Yokohama City Univ Med, Infect Prevent & Control Dept, Yokohama, Japan

[18] Saitama Med Ctr, Dept Gen Internal Med & Infect Dis, Saitama, Japan

[19] Sano Kosei Gen Hosp, Dept Internal Med, Tochigi, Japan

[20] St Lukes Int Hosp, Dept Pulm Med, Tokyo, Japan

[21] Asahi Gen Hosp, Dept Internal Med, Chiba, Japan

[22] Showa Gen Hosp, Dept Pediat, Tokyo, Japan

[23] Showa Gen Hosp, Dept Infect Dis, Tokyo, Japan

[24] NATURALI Co Ltd, Tokyo, Japan

来源：

OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 06期

关键词：

COVID-19; SARS-CoV-2; variants; test-negative design; vaccine effectiveness;

D O I：

10.1093/ofid/ofad240

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined). In this multi-center study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent vaccines against symptomatic infection during the BA.5-dominant period was high compared to no vaccination (65%/76%) and moderate compared to monovalent vaccines >6 months before (46% combined).

引用

页数：6

共 50 条

[21] Omicron Subvariants, Including BA.4 and BA. 5, Substantially Preserve T Cell Epitopes of Ancestral SARS-CoV-2
Park, Kyemyung
Choi, Seung Jin
Shin, Eui-Cheol
IMMUNE NETWORK, 2022, 22 (04)
[22] SARS-CoV-2 Omicron variants BA.4 and BA.5 dominated the fifth COVID-19 epidemiological wave in Mexico
Taboada, Blanca Itzelt
Zarate, Selene
Garcia-Lopez, Rodrigo
Munoz-Medina, Jose Esteban
Gomez-Gil, Bruno
Herrera-Estrella, Alfredo
Sanchez-Flores, Alejandro
Salas-Lais, Angel Gustavo
Roche, Benjamin
Martinez-Morales, Gabriela
Zarate, Hermilo Dominguez
Molina, Celida Duque
Hernandez, Ricardo Aviles
Lopez, Susana
Arias, Carlos F.
MICROBIAL GENOMICS, 2023, 9 (12):
[23] Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
Hachmann, Nicole P.
Miller, Jessica
Collier, Ai-ris Y.
Ventura, John D.
Yu, Jingyou
Rowe, Marjorie
Bondzie, Esther A.
Powers, Olivia
Surve, Nehalee
Hall, Kevin
Barouch, Dan H.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (01): : 86 - 88
[24] Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
Wang, Qian
Guo, Yicheng
Iketani, Sho
Nair, Manoj S.
Li, Zhiteng
Mohri, Hiroshi
Wang, Maple
Yu, Jian
Bowen, Anthony D.
Chang, Jennifer Y.
Shah, Jayesh G.
Nguyen, Nadia
Chen, Zhiwei
Meyers, Kathrine
Yin, Michael T.
Sobieszczyk, Magdalena E.
Sheng, Zizhang
Huang, Yaoxing
Liu, Lihong
Ho, David D.
NATURE, 2022, 608 (7923) : 603 - +
[25] Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents
Ryuta Uraki
Peter J. Halfmann
Shun Iida
Seiya Yamayoshi
Yuri Furusawa
Maki Kiso
Mutsumi Ito
Kiyoko Iwatsuki-Horimoto
Sohtaro Mine
Makoto Kuroda
Tadashi Maemura
Yuko Sakai-Tagawa
Hiroshi Ueki
Rong Li
Yanan Liu
Deanna Larson
Shuetsu Fukushi
Shinji Watanabe
Ken Maeda
Andrew Pekosz
Ahmed Kandeil
Richard J. Webby
Zhongde Wang
Masaki Imai
Tadaki Suzuki
Yoshihiro Kawaoka
Nature, 2022, 612 : 540 - 545
[26] Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
Qian Wang
Yicheng Guo
Sho Iketani
Manoj S. Nair
Zhiteng Li
Hiroshi Mohri
Maple Wang
Jian Yu
Anthony D. Bowen
Jennifer Y. Chang
Jayesh G. Shah
Nadia Nguyen
Zhiwei Chen
Kathrine Meyers
Michael T. Yin
Magdalena E. Sobieszczyk
Zizhang Sheng
Yaoxing Huang
Lihong Liu
David D. Ho
Nature, 2022, 608 : 603 - 608
[27] Effectiveness of mRNA-1273 bivalent (original and omicron BA.4/BA.5) COVID-19 vaccine against hospitalizations for COVID-19, medically attended SARS-CoV-2 infections, and COVID-19 hospital deaths in the United States
Tseng, Hung Fu
Ackerson, Bradley K.
Sy, Lina S.
Tubert, Julia E.
Luo, Yi
Qiu, Sijia
Bruxvoort, Katia J.
Lee, Gina S.
Ku, Jennifer H.
Florea, Ana
Takhar, Harpreet S.
Zhou, Cindy Ke
Esposito, Daina
Chavers, Scott
Talarico, Carla A.
Qian, Lei
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 609 - 609
[28] BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
Tartof, Sara Y.
Slezak, Jeff M.
Puzniak, Laura
Hong, Vennis
Frankland, Timothy B.
Ackerson, Bradley K.
Takhar, Harpreet
Ogun, Oluwaseye A.
Simmons, Sarah
Zamparo, Joann M.
Jodar, Luis
McLaughlin, John M.
LANCET INFECTIOUS DISEASES, 2022, 22 (12): : 1663 - 1665
[29] Effectiveness of Adapted COVID-19 Vaccines and Ability to Establish Herd Immunity against Omicron BA.1 and BA4-5 Variants of SARS-CoV-2
Plans-Rubio, Pedro
VACCINES, 2023, 11 (12)
[30] SARS-CoV-2 Omicron (BA.4, BA.5) variant: Lessons learned from a new variant during the COVID-19 pandemic
Erabi, Gisou
Faridzadeh, Arezoo
Parvin, Ali
Deravi, Niloofar
Rahmanian, Mohammad
Fathi, Mobina
Aleebrahim-Dehkordi, Elahe
Rezaei, Nima
HEALTH SCIENCE REPORTS, 2024, 7 (02)

← 1 2 3 4 5 →